本文へ移動
cccskills
無料GitHub で公開

es-hcm-para-carcinoma-refractory-bp-dmab-add-calcimimetic

The skill suggests adding a calcimimetic for hypercalcemia of malignancy due to parathyroid carcinoma that persists after intravenous bisphosphonate or denosumab therapy. It is triggered when a clinician notes refractory HCM despite antiresorptive therapy and considers adding a calcimimetic.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.7 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Add calcimimetic for parathyroid carcinoma HCM refractory to bisphosphonate/denosumab

STEP 1 — Gather Information

Confirm parathyroid carcinoma diagnosis, obtain serum calcium and albumin to calculate albumin-adjusted calcium, document current IV bisphosphonate (e.g., zoledronic acid) or denosumab regimen (dose, frequency, duration), assess symptoms (fatigue, polyuria, nausea), and check renal function (eGFR).
Action: Record adjusted serum calcium, therapy details, symptoms, and eGFR.

STEP 2 — Rule In / Rule Out

Is hypercalcemia due to parathyroid carcinoma and refractory to intravenous bisphosphonate or denosumab therapy (persistent adjusted calcium >10.5 mg/dL despite adequate antiresorptive therapy)?

  • If Yes, proceed to Step 3.
  • If No, consider alternative etiologies or adjust current antiresorptive therapy; stop this algorithm.

STEP 3 — Classify or Stratify

Classify severity of hypercalcemia based on albumin-adjusted serum calcium: mild (<12 mg/dL), moderate (12–14 mg/dL), severe (>14 mg/dL).
Action: Assign severity category and document.

STEP 4 — Decide

Add a calcimimetic (e.g., cinacalcet) starting at 30 mg PO twice daily; titrate every 2–4 weeks by 30 mg increments to achieve adjusted calcium <10.5 mg/dL, monitoring serum calcium weekly until stable then monthly.
Action: Initiate calcimimetic and arrange calcium monitoring.

Clinical Guardrails / Mimics / Pitfalls

Monitor for hypocalcemia (especially if eGFR <30 mL/min) and gastrointestinal adverse effects (nausea, vomiting); do not use calcimimetic as sole therapy for acute severe HCM with symptomatic hypercalcemia >14 mg/dL without urgent hydration and antiresorptive therapy; avoid in patients with known severe hepatic impairment without dose adjustment; consider surgical resection if feasible despite medical control.

Concrete Clinical Example

A 68-year-old with metastatic parathyroid carcinoma on monthly IV zoledronic acid 4 mg has persistent fatigue and polyuria; albumin-adjusted calcium is 13.9 mg/dL. Cinacalcet 30 mg PO BID is started, titrated to 60 mg BID after 3 weeks, resulting in adjusted calcium of 9.8 mg/dL and symptom resolution.

Source: Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する